# Target specificity of human RNA-induced silencing complex

> **NIH NIH R01** · OHIO STATE UNIVERSITY · 2024 · $145,300

## Abstract

Summary/Abstract of Parent Award Project
In eukaryotic cells, gene expression is regulated at multiple levels, including post-transcriptional
gene silencing, where microRNAs (miRNAs) bind to complementary target RNAs and cause
translational repression. Argonaute (AGO) proteins and miRNAs form RNA-induced silencing
complexes (RISCs), the core players in gene silencing. Humans have four AGO proteins, AGO1-4,
which share a high sequence identity, and the majority of miRNAs bound are common across all
AGOs. Therefore, it has been thought that the four AGOs work redundantly. Nevertheless, an
increasing number of studies have found that each AGO has its unique roles in various biological
processes and diseases in addition to gene silencing. Although the interaction of all four AGOs with
miRNAs has been well characterized, little is known about how each RISC recognizes its target
RNAs. Elucidation of this recognition will provide insight into the unique roles of each AGO.
Meanwhile, the characterization of RISC and target interactions will facilitate target prediction
accuracy by improving prediction algorithms, which will take into account not only the
complementarity between guide and target but also the type of AGO and target interaction. In this
proposed study, we will pursue the following specific aims. In Aim 1, we will use cryo-electron
microscopy and X-ray crystallography to determine the structures of all four homogenously purified
RISCs with the same guide and target RNAs, which will provide insight into the differences in target
recognition by the four AGOs. In Aim 2, to clarify these differences, we recently developed a novel
SHAPE-based technique that allows us to visualize the conformational dynamics of target RNA
bound to RISC. The method will enable us to characterize this interaction within the RISC binding
channel and its periphery at a single-nucleotide resolution and can be expanded to understand how
RISCs recognize guide-binding sites buried within highly structured target RNAs. In Aim 3, we will
first use mass spectrometry to identify the unique protein binding partners of each AGO and their
specific sites of interaction. Then, we will use tandem immunoprecipitation, followed by RNA
sequencing, to determine how the binding of these proteins influences the target specificity of each
AGO and directs their functionality toward alternative cellular events. The outcome of this study will
provide a solid foundation for fields beyond gene silencing and enable the development of new
strategies for higher accuracy guide-RNA drug design in therapeutic applications.

## Key facts

- **NIH application ID:** 11036442
- **Project number:** 3R01GM124320-07S1
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Kotaro Nakanishi
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $145,300
- **Award type:** 3
- **Project period:** 2017-09-15 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11036442

## Citation

> US National Institutes of Health, RePORTER application 11036442, Target specificity of human RNA-induced silencing complex (3R01GM124320-07S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11036442. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
